Injury of liver
Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment
Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline
FDA Updates Label for Agios’ PYRUKYND with New Liver Injury Warning
Agios Pharmaceuticals, PYRUKYND, mitapivat, liver injury warning, FDA label update, thalassemia treatment
FDA Warns of Serious Liver Injury Risk with Ocaliva (Obeticholic Acid) in Patients with Primary Biliary Cholangitis
Ocaliva, obeticholic acid, liver injury, FDA warning, primary biliary cholangitis, liver disease, medication safety
Ocaliva (Obeticholic Acid) Linked to Increased Risk of Liver Failure in PBC Patients Without Cirrhosis
Ocaliva, obeticholic acid, primary biliary cholangitis (PBC), liver failure, liver injury, cirrhosis, FDA warning.
Agios’ Thalassemia Drug Mitapivat Faces Liver Injury Concerns Despite Second Phase III Success
Agios Pharmaceuticals, Mitapivat, Thalassemia, Liver Injury, Phase III Trials, ENERGIZE-T Study, Regulatory Approval
FDA Issues Warning on Rare Liver Injury Risk with Veozah (Fezolinetant) for Menopausal Hot Flashes
Veozah (fezolinetant), FDA warning, Liver injury, Menopausal hot flashes, Nonhormonal prescription medicine, Neurokinin 3 (NK3) receptor antagonists